Anúncio
Anúncio

TMDX

TMDX logo

TransMedics Group, Inc. Common Stock

137.18
USD
Patrocinado
-0.39
-0.28%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

138.50

+1.33
+0.97%

Relatórios de Lucros TMDX

Rácio de surpresa positiva

TMDX separação 17 de 27 últimas estimativas.

63%

Próximo Relatório

Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$158.48M
/
$0.39
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+10.19%
/
-40.91%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+30.31%
/
+105.26%

TransMedics Group, Inc. Common Stock earnings per share and revenue

On 29 de out. de 2025, TMDX reported earnings of 0.66 USD per share (EPS) for Q3 25, beating the estimate of 0.35 USD, resulting in a 84.41% surprise. Revenue reached 143.82 milhão, compared to an expected 148.16 milhão, with a -2.93% difference. The market reacted with a +1.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analistas forecast an EPS of 0.39 USD, with revenue projected to reach 158.48 milhão USD, implying an diminuir of -40.91% EPS, and aumentar of 10.19% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
For Q3 2025, TransMedics Group, Inc. Common Stock reported EPS of $0.66, beating estimates by 84.41%, and revenue of $143.82M, -2.93% below expectations.
The stock price moved up 1.09%, changed from $134.32 before the earnings release to $135.79 the day after.
The next earning report is scheduled for 25 de fev. de 2026.
Based on 14 analistas, TransMedics Group, Inc. Common Stock is expected to report EPS of $0.39 and revenue of $158.48M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio